Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 (TMB-202)

This study has been completed.
Information provided by (Responsible Party):
TaiMed Biologics Inc. Identifier:
First received: October 30, 2008
Last updated: December 17, 2012
Last verified: December 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2011
  Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)